Tag: Eczema
AAD: Maintenance of Low Eczema Activity Seen After About 80 Days Off Tapinarof
Many patients who achieved clear skin with tapinarof treatment maintained low disease activity after treatment-free interval
Early Childhood Stressful Life Events Linked to Increased Eczema Activity
Association driven by common stressful life events such as starting new school, having new baby sibling
Study IDs Signs of Topical Steroid Withdrawal in Atopic Dermatitis
The most reported signs were erythema, desquamation, dryness, and oozing affecting the face, neck, and upper extremities
FDA Expands Approval of Vtama to Include Atopic Dermatitis
The nonsteroidal topical treatment is approved for patients 2 years and older
FDA Approves Nemluvio for Moderate-to-Severe Atopic Dermatitis
The monoclonal antibody treatment is for patients ages 12 years and older
Dupilumab Efficacious for Atopic Dermatitis in Young Children
Findings seen for children with and without comorbidities, such as asthma, allergic rhinitis, food allergies
Greater Fine Particulate Matter Linked to Increased Odds of Eczema
In multivariable analyses after adjustment for demographics and smoking status, odds ratio was 2.21 for eczema in areas with higher PM2.5
Long-Term Upadacitinib Use Feasible for Adolescents With Atopic Dermatitis
Findings seen through 76 weeks of treatment for adolescents taking 15- or 30-mg doses for moderate-to-severe atopic dermatitis
Long-Term Efficacy for Lebrikizumab Seen in Moderate, Severe Eczema
Long-term efficacy seen for lebrikizumab every two weeks or every four weeks in moderate-to-severe atopic dermatitis
FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis
Approval is for new, first-line biologic treatment of eczema that is not well controlled with topicals in people 12 years and older
